Analyst Price Target Update on Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ:SGEN) stock has received a short term price target of $ 44.9 from 10 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $9.85. The higher estimate of target price is $65 , while the lower price target estimate is $33

Many analysts have stated their opinion on the company shares. SunTrust Robinson Humphrey initiates coverage on Seattle Genetics (NASDAQ:SGEN) The current rating of the shares is Neutral. Equity Analysts at the Firm announces the price target to $34 per share. The rating by the firm was issued on March 3, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, Siegall Clay B, director officer (President and CEO) of Seattle Genetics Inc /Wa, unloaded 22,083 shares at an average price of $43.57 on June 6, 2016. The total amount of the transaction was worth $962,156, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Seattle Genetics (NASDAQ:SGEN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.07 points or 2.65% at $39.31 with 1,002,085 shares getting traded. Post opening the session at $40.11, the shares hit an intraday low of $38.6 and an intraday high of $40.41 and the price was in this range throughout the day. The company has a market cap of $5,510 million and the number of outstanding shares have been calculated to be 140,167,030 shares. The 52-week high of Seattle Genetics (NASDAQ:SGEN) is $52.3299 and the 52-week low is $26.02.

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Companys marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Companys pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics sugar-engineered antibody (SEA) technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *